Voxar launches calcium scoring package

Article

An advanced calcium scoring application developed by the Scottish firm Voxar has cleared the FDA. Voxar Calscreen 2.1 is designed to detect, quantify, and report the presence of calcium plaque in the coronary arteries. It complements the company's

An advanced calcium scoring application developed by the Scottish firm Voxar has cleared the FDA. Voxar Calscreen 2.1 is designed to detect, quantify, and report the presence of calcium plaque in the coronary arteries. It complements the company's flagship Plug n View 3D and Voxar Colonscreen products. The package automates the identification of calcified plaques in the coronary arteries and calculates the calcium score, providing the basis for assessing potential risk and managing associated coronary heart disease before symptoms arise. Calscreen 2.1 works with electron-beam tomography scanners and multislice or helical CTs. The package, which runs on a standard PC, automatically highlights calcified regions in red as part of multiplanar reformatted (MPR) and 3D views of the heart.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.